Cardiovascular Research Advance Access [Accepted Manuscript] published online on July 9, 2008
Cardiovascular Research, doi:10.1093/cvr/cvn181
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Control of cardiac excitability by microRNAs
1 Department of Pharmacology (the State-Province Key Laboratories of Biomedicine-Pharmaceutics of China)
2 Cardiovascular Research Institute, Harbin Medical University, Harbin, Heilongjiang 150086, P. R. China
3 Research Center, Montreal Heart Institute, Montreal, PQ H1T 1C8 Canada
4 Department of Medicine, University of Montreal, Montreal, PQ H3C 3J7, Canada
* Corresponding Author: Dr. Zhiguo Wang, PhD; Research Center, Montreal Heart Institute, 5000 Belanger East, Montreal, PQ H1T 1C8, Canada; Tel.: (514) 376-3330. Fax: (514) 376-4452; E-mail: wz.email{at}gmail.com; or Dr. Baofeng Yang, MD, PhD; Department of Pharmacology (State-Province key lab of China), Harbin Medical University, Harbin, Heilongjiang 150086 P.R. China; Tel. +86 451 8667-9473; E-mail: yangbf{at}ems.hrbmu.edu.cn
Cardiovascular disease is the leading cause of morbidity and mortality in developed countries. The pathological process of the heart is associated with altered an expression profile of genes that are important for cardiac function. Micro RNAs (miRNAs) have recently emerged as one of the central players of gene expression regulation. The implications of miRNAs in the pathological process of the cardiovascular system have recently been recognized, and the research on miRNAs in relation to cardiovascular disease has now become a most rapidly evolving field. In this review article, we focus on miRNAs and control of cardiac excitability, aiming to provide a comprehensive overview on the available experimental data on regulation of cardiac conduction, repolarization and automaticity by miRNAs. Aberrant expression of miRNAs in diseased states of the heart and their arrhythmogenic or antiarrhythmic potential will be discussed. Finally, the innovative miRNA-interference technologies developed lately for manipulating the actions of miRNAs by interfering with their expression, stability and function as new approaches for miRNA research and gene therapy will be introduced.
KEYWORDS miRNA; arrhythmias; cardiac excitability; ion channels; gene expression
Time for primary review: 25 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Goette Nicotine, atrial fibrosis, and atrial fibrillation: do microRNAs help to clear the smoke? Cardiovasc Res, August 1, 2009; 83(3): 421 - 422. [Full Text] [PDF]
|
|
|
|
|
|
Y. Lu, Y. Zhang, H. Shan, Z. Pan, X. Li, B. Li, C. Xu, B. Zhang, F. Zhang, D. Dong, et al. MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: a new mechanism for ischaemic cardioprotection Cardiovasc Res, July 31, 2009; (2009) cvp232v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Qin, B. Zhao, Y. Shi, C. Yao, L. Jin, and Y. Jin BMPRII is a direct target of miR-21 Acta Biochim Biophys Sin, July 1, 2009; 41(7): 618 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Condorelli and S. Dimmeler MicroRNAs: components of an integrated system controlling cardiac development, physiology, and disease pathogenesis Cardiovasc Res, September 1, 2008; 79(4): 551 - 552. [Full Text] [PDF]
|
|